Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3120240 | 0.98 | ESR1 (1.00) | ESR1ESR2 | |
| Hydrochloric Acid SCHEMBL3121892 | 0.97 | ESR1 (1.00) | ESR1ESR2 | |
| Succinic Acid SCHEMBL3113603 | 0.94 | ESR1 (0.91) | ESR1ESR2 | |
| SCHEMBL3115268 | 0.91 | ESR1 (1.00) | ESR1ESR2 | |
| Hydrochloric Acid SCHEMBL3109037 | 0.90 | ESR1 (0.83) | ESR1ESR2 | |
| Hydrochloric Acid SCHEMBL3119607 | 0.90 | ESR1 (0.98) | ESR1ESR2 | |
| SCHEMBL3118086 | 0.89 | ESR1 (1.00) | ESR1ESR2 | |
| SCHEMBL3118961 | 0.89 | ESR1 (0.83) | ESR1ESR2 | |
| Bromide SCHEMBL29084474 | 0.89 | ESR1 (0.83) | ESR1ESR2 | |
| SCHEMBL13390058 | 0.89 | ESR1 (0.82) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1530470-B9 | SELECTIVE ESTROGEN RECEPTOR MODULATORS CONTAINING A PHENYLSULFONYL GROUP | LILLY CO ELI (US) | 2010-04-07 | — | — | EP | disclosed |
| US-7585977-B2 | Selective estrogen receptor modulators containing a phenylsulfonyl group | ELI LILLY AND COMPANY (US) | 2009-09-08 | — | — | US | disclosed |
| EP-1530470-B1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS CONTAINING A PHENYLSULFONYL GROUP | LILLY CO ELI (US) | 2009-06-10 | — | — | EP | disclosed |
| US-20080214612-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS CONTAINING A PHENYLSULFONYL GROUP | DALLY ROBERT DEAN | 2008-09-04 | — | — | US | disclosed |
| US-7399867-B2 | Selective estrogen receptor modulators containing a phenylsulfonyl group | ELI LILLY AND COMPANY (US) | 2008-07-15 | — | — | US | disclosed |
| EP-1782810-A2 | Selective estrogen receptor modulators containing a phenylsulfonyl group | Eli Lilly & Company (US) | 2007-05-09 | — | — | EP | disclosed |
| US-20060183736-A1 | Selective estrogen receptor modulators containing a phenylsulfonyl group | ELILILLY AND COMPANY | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214612-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS CONTAINING A PHENYLSULFONYL GROUP | GPER1, ESR2, ESR1 | ESR1 3/4885ESR2 2/4885 |
| US-20060183736-A1 | Selective estrogen receptor modulators containing a phenylsulfonyl group | GPER1, ESR2, ESR1 | ESR1 3/4885ESR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.